Theravance Biopharma Profit Margin

Theravance Biopharma (TBPH) currently reports a profit margin of 51.58% as of June 2026. That compares with 16.88% in the prior-year period — up 205.6% year over year. That is above the Healthcare sector average of 21.34%. Use the charts on this page to explore Theravance Biopharma's profit margin history and peer comparisons.

Theravance Biopharma's profit margin increased from 16.88% to 51.58% — a 205.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Theravance Biopharma's profit margin of 51.58% is higher than the Healthcare sector average of 21.34%. That is roughly 141.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Theravance Biopharma's current 51.58% should be judged against Healthcare norms (sector average: 21.34%) and against TBPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 51.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Theravance Biopharma, and consider following TBPH for alerts when major investors trade the stock.